|
Market Closed -
NYSE
04:00:02 2026-11-17 pm EST
|
5-day change | 1st Jan Change | ||
| 182.27 USD | -0.95% |
|
-2.40% | +98.27% |
| Nov. 17 | Merck stops trials of blood cancer drug after review of risks | RE |
| Nov. 17 | AstraZeneca PLC : Jefferies gives a Buy rating | ZD |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 282,970 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -1.68% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 303,802 | 296,618 | 287,608 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -2.37% | -2.36% | -3.04% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 23.9x | 20.6x | 18.2x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 5.26x | 4.56x | 3.92x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.4x | 1.3x | 1.4x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.46x | 4.2x | 3.96x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.79x | 4.4x | 4.02x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 13.5x | 12.1x | 10.6x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 14.3x | 12.7x | 11.3x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 33.3x | 23.6x | 19.6x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.01% | 4.24% | 5.09% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.331 | 3.543 | 3.656 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 1.83% | 1.94% | 2% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.625 | 8.854 | 10.01 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43.7% | 40% | 36.5% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,376 | 67,393 | 71,464 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,571 | 24,455 | 27,029 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,287 | 23,272 | 25,551 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 11,692 | 13,578 | 15,280 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 20,832 | 13,648 | 4,638 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 182.44 | 182.44 | 182.44 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,043 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/6/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 41.9x | 14.18x | 30.07x | 0.48% | 1,261B | ||
| 41.35x | 6.94x | 19.51x | 1.89% | 671B | ||
| 37.55x | 8.61x | 17.78x | 2.34% | 518B | ||
| 22x | 5.33x | 13.34x | 2.45% | 387B | ||
| 102.54x | 5.86x | 24.97x | 2.35% | 353B | ||
| 24.41x | 5.87x | 14.28x | 2.7% | 300B | ||
| 24.28x | 4.86x | 13.64x | 1.8% | 283B | ||
| 23.87x | 7.33x | 13.47x | 2.18% | 248B | ||
| -39.41x | 7.29x | 45.94x | 1.97% | 211B | ||
| Average | 30.94x | 7.36x | 21.45x | 2.02% | 470B | |
| Weighted average by Cap. | 37.00x | 8.89x | 22.54x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
















